构建结核分枝杆菌复合群耐药相关突变二代测序数据标准化临床实验室报告框架
结核病仍是全球首要致死性传染病,耐多药威胁加剧,传统表型药敏试验难以满足快速全面检测需求,二代测序(NGS)提供快速全面药敏潜力。本文总结两次专家研讨会,聚焦标准化报告格式的相关变量、术语及临床和实验室报告最低要素,提出结核分枝杆菌NGS结果临床报告的标准化模板。
要点
- NGS可快速全面检测结核分枝杆菌耐药突变,但需标准化报告确保结果清晰一致可比。
- 专家研讨会提出NGS耐药突变报告应包含相关变量、术语及最低报告要素。
- 建议采用标准化模板用于结核分枝杆菌NGS耐药突变的临床报告。
核心结论
- 随着NGS可及性扩大,需确保结核分枝杆菌耐药突变检测结果沟通清晰、一致、实验室间可比,并附明确临床解读指导。
研究设计与样本
- 观点文章,总结两次专家研讨会关于标准化报告格式的讨论。
主要发现
- 研讨会聚焦NGS耐药突变临床和实验室报告的相关变量、术语及最低要素,并提出标准化临床报告模板。
临床怎么用
- 临床实验室报告结核分枝杆菌NGS耐药突变结果时,可参考提出的标准化模板,确保包含相关变量、术语和最低要素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculosis is the primary infectious disease killer worldwide, with a growing threat from multidrug-resistant cases. Unfortunately, classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, costly, and time consuming, while current rapid molecular testing options are limited by the diversity of antimicrobial-resistant genotypes that can be detected at once. Next-generation sequencing (NGS) offers the opportunity for rapid, comprehensive DST without the time or cost burden of phenotypic tests and can provide useful information for global surveillance. As access to NGS expands, it will be important to ensure that results are communicated clearly, consistent, comparable between laboratories, and associated with clear guidance on clinical interpretation of results. In this viewpoint article, we summarize 2 expert workshops regarding a standardized report format, focusing on relevant variables, terminology, and required minimal elements for clinical and laboratory reports with a proposed standardized template for clinical reporting NGS results for Mycobacterium tuberculosis.
引用
- Tornheim JA, Starks AM, Rodwell TC, et al. Building the Framework for Standardized Clinical Laboratory Reporting of Next-generation Sequencing Data for Resistance-associated Mutations in Mycobacterium tuberculosis Complex. Clin Infect Dis. 2019. PMID: 30883637. doi:10.1093/cid/ciz219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。